7.59
+0.02(+0.26%)
Currency In USD
| Previous Close | 7.59 |
| Open | 7.64 |
| Day High | 8.09 |
| Day Low | 7.54 |
| 52-Week High | 8.25 |
| 52-Week Low | 3.54 |
| Volume | 199,688 |
| Average Volume | 133,613 |
| Market Cap | 176.81M |
| PE | -20.51 |
| EPS | -0.37 |
| Moving Average 50 Days | 7.16 |
| Moving Average 200 Days | 5.9 |
| Change | 0.02 |
If you invested $1000 in Journey Medical Corporation (DERM) since IPO date, it would be worth $766.67 as of July 30, 2025 at a share price of $7.59. Whereas If you bought $1000 worth of Journey Medical Corporation (DERM) shares 2 years ago, it would be worth $1,936.22 as of July 30, 2025 at a share price of $7.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
GlobeNewswire Inc.
Jul 14, 2025 12:30 PM GMT
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) --
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
GlobeNewswire Inc.
Jun 24, 2025 12:30 PM GMT
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Foo
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
GlobeNewswire Inc.
Jun 20, 2025 12:30 PM GMT
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosaceaSCOTTSDALE, Ariz., June 20, 2025 (GLOB